IL23A and inflammatory bowel disease: Preclinical data in murine models of colitis highlighted the importance of this cytokine in IBD (37); several anti–IL-23p19–specific antibodies, including risankizumab, brazikumab, mirikizumab, and guselkumab, have been or are currently under evaluation in clinical trials in CD and, in some cases, UC (38).